The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Journal for ImmunoTherapy of Cancer

Volumn 4, Issue 1, 2016, Pages

  McNeel, Douglas G ^a   Bander, Neil H ^b   Beer, Tomasz M ^c   Drake, Charles G ^d   Fong, Lawrence ^e   Harrelson, Stacey ^f   Kantoff, Philip W ^g   Madan, Ravi A ^h   Oh, William K ⁱ   Peace, David J ^j   Petrylak, Daniel P ^k   Porterfield, Hank ^l   Sartor, Oliver ^m   Shore, Neal D ^f   Slovin, Susan F ^g   Stein, Mark N ⁿ   Vieweg, Johannes ^o   Gulley, James L ^p  

^a UNIVERSITY OF WISCONSIN   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Carolina Urologic Research Center   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^k YALE CANCER CENTER   (United States)

^l Alliance for Prostate Cancer Prevention   (United States)

^m TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^o NOVA SOUTHEASTERN UNIVERSITY   (United States)

^p Genitourinary Malignancies Branch   (United States)

more..

Author keywords

Guidelines; Immunotherapy; Prostate cancer; Treatment

Indexed keywords

ABIRATERONE; CABAZITAXEL; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOCETAXEL; ENZALUTAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROGRAMMED DEATH 1 LIGAND 1; RADIUM CHLORIDE RA 223; SIPULEUCEL T; TUMOR VACCINE;

ABLATION THERAPY; ANDROGEN DEPRIVATION THERAPY; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD CELL COUNT; CANCER IMMUNOTHERAPY; CORTICOSTEROID THERAPY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CARCINOMA;

EID: 85006741962     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-016-0198-x     Document Type: Article

References (61)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30. doi: 10.3322/caac.21332.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29. doi: 10.3322/caac.21254.
3. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273(7):548-52.
4. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-97. doi: 10.1056/NEJMoa1207506.
5. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983-92. doi: 10.1016/s1470-2045(12)70379-0.
6. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138-48. doi: 10.1056/NEJMoa1209096.
7. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-54. doi: 10.1016/s0140-6736(10)61389-x.
8. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213-23. doi: 10.1056/NEJMoa1213755.
9. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-22. doi: 10.1056/NEJMoa1001294.
10. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24(19):3089-94. doi: 10.1200/jco.2005.04.5252.
11. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(16):3670-9. doi: 10.1002/cncr.24429.
12. Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods. 2009;348(1-2):9-17. doi: 10.1016/j.jim.2009.06.004.
13. Sfanos KS, Bruno TC, Meeker AK, De Marzo AM, Isaacs WB, Drake CG. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate. 2009;69(15):1694-703. doi: 10.1002/pros.21020.
14. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A. 2001;98(25):14565-70. doi: 10.1073/pnas.251140998.
15. McNeel DG, Nguyen LD, Ellis WJ, Higano CS, Lange PH, Disis ML. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. Prostate. 2001;47(3):222-9. doi: 10.1002/pros.1066.
16. Olson BM, McNeel DG. Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer. Prostate. 2007;67(16):1729-39. doi: 10.1002/pros.20652.
17. Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, et al. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst. 1995;87(4):280-5.
18. Bander NH, Yao D, Liu H, Chen YT, Steiner M, Zuccaro W, et al. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate. 1997;33(4):233-9.
19. Gulley JL, Madan RA, Heery CR. Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications. Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e166.
20. Slovin SF. Immunotherapeutic approaches in prostate cancer: combinations and clinical integration. Am Soc Clin Oncol Educ Book. 2015:e275-83. doi: 10.14694/EdBook_AM.2015.35.e275
21. van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):509-17. doi: 10.1016/s1470-2045(12)70007-4.
22. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099-105. doi: 10.1200/jco.2009.25.0597.
23. McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol. 2009;27(25):4047-54. doi: 10.1200/jco.2008.19.9968.
24. Eriksson F, Totterman T, Maltais AK, Pisa P, Yachnin J. DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer. Vaccine. 2013;31(37):3843-8. doi: 10.1016/j.vaccine.2013.06.063.
25. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700-12. doi: 10.1016/s1470-2045(14)70189-5.
26. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54. doi: 10.1056/NEJMoa1200690.
27. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167-75. doi: 10.1200/jco.2009.26.7609.
28. Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY, et al. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother. 2013;62(1):137-47. doi: 10.1007/s00262-012-1317-2.
29. National Comprehensive Cancer Network. Prostate Cancer (Version 3.2016). https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 24 Oct 2016.
30. European Association of Urology. Prostate Cancer. http://uroweb.org/guideline/prostate-cancer/. Accessed 24 Oct 2016.
31. Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American society of clinical oncology and cancer care Ontario clinical practice guideline. J Clin Oncol. 2014;32(30):3436-48. doi: 10.1200/jco.2013.54.8404.
32. Lowrance WT, Roth BJ, Kirkby E, Murad MH, Cookson MS. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015. J Urol. 2015. doi: 10.1016/j.juro.2015.10.086.
33. Simpson EL, Davis S, Thokala P, Breeze PR, Bryden P, Wong R. Sipuleucel-T for the treatment of metastatic hormone-relapsed prostate cancer: a nice single technology appraisal; an evidence review group perspective. Pharmacoecon. 2015;33(11):1187-94. doi: 10.1007/s40273-015-0296-5.
34. Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, editors. Clinical Practice Guidelines We Can Trust. Washington (DC): National Academies Press (US); 2011. https://www.ncbi.nlm.nih.gov/pubmed/24983061.
35. Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, et al. The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013;10(10):588-98. doi: 10.1038/nrclinonc.2013.153.
36. Society for Immunotheray of Cancer (SITC). Cancer Immunotherapy Guidelines. 2013. http://www.sitcancer.org/about-sitc/initiatives/cancer-immunotherapy-guidelines. Accessed 04 Aug 2016.
37. Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial. Urology. 2013;81(6):1297-302. doi: 10.1016/j.urology.2013.01.061.
38. Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res. 2011;17(13):4558-67. doi: 10.1158/1078-0432.ccr-10-3223.
39. Botrel TE, Clark O, Pompeo AC, Bretas FF, Sadi MV, Ferreira U, et al. Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis. Int Braz J Urol. 2012;38(6):717-27.
40. Mulders PF, De Santis M, Powles T, Fizazi K. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Cancer Immunol Immunother. 2015;64(6):655-63. doi: 10.1007/s00262-015-1707-3.
41. GuhaThakurta D, Sheikh NA, Fan LQ, Kandadi H, Meagher TC, Hall SJ, et al. Humoral immune response against nontargeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome. Clin Cancer Res. 2015;21(16):3619-30. doi: 10.1158/1078-0432.ccr-14-2334.
42. Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014;106(11). doi: 10.1093/jnci/dju268.
43. Singh BH, Gulley JL. Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. Asian J Androl. 2014;16(3):364-71. doi: 10.4103/1008-682x.122585.
44. Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, et al. A randomized phase II trial of sipuleucel-T with concurrent versus sequential abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2015;21(17):3862-9. doi: 10.1158/1078-0432.ccr-15-0079.
45. Sheikh NA, Jones LA. CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother. 2008;57(9):1381-90. doi: 10.1007/s00262-008-0474-9.
46. Thara E, Dorff TB, Averia-Suboc M, Luther M, Reed ME, Pinski JK, et al. Immune response to sipuleucel-T in prostate cancer. Cancers (Basel). 2012;4(2):420-41. doi: 10.3390/cancers4020420.
47. Antonarakis E KA, Adams G, Karsh L, Elfiky A, Shore N. A randomized phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer: Immune results with a focus on humoral responses. Proceedings of the European Association of Andrology Annual Congress, Stockholm. 2014;11-15 April(Poster 980).
48. Quinn DI, Shore ND, Egawa S, Gerritsen WR, Fizazi K. Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms. Urol Oncol. 2015;33(5):245-60. doi: 10.1016/j.urolonc.2014.10.009.
49. McNeel DG, Gardner TA, Higano CS, Kantoff PW, Small EJ, Wener MH, et al. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T. Cancer Immunol Res. 2014;2(10):988-99. doi: 10.1158/2326-6066.cir-14-0073.
50. US Food and Drug Administration. Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines. 2011. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM278673.pdf. Accessed 16 Nov 2016
51. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-20. doi: 10.1158/1078-0432.ccr-09-1624.
52. Kawalec P, Paszulewicz A, Holko P, Pilc A. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis. Arch Med Sci. 2012;8(5):767-75. doi: 10.5114/aoms.2012.31610.
53. Fitch K, Pyenson B. Cancer patients recieving chemotherapy: opportunities for better management. Client Report. 2010;30:1-27.
54. DiPaola RS, Chen YH, Bubley GJ, Stein MN, Hahn NM, Carducci MA, et al. A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. Eur Urol. 2015;68(3):365-71. doi: 10.1016/j.eururo.2014.12.010.
55. McNeel DG, Chen YH, Gulley JL, Dwyer AJ, Madan RA, Carducci MA, et al. Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). Hum Vaccin Immunother. 2015;11(10):2469-74. doi: 10.1080/21645515.2015.1062190.
56. Karan D, Van Veldhuizen P. Combination immunotherapy with prostate GVAX and ipilimumab: safety and toxicity. Immunotherapy. 2012;4(6):577-80. doi: 10.2217/imt.12.53.
57. Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, et al. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. Cancer Immunol Immunother. 2014;63(4):407-18. doi: 10.1007/s00262-014-1524-0.
58. Gulley JL, Madan RA, Tsang KY, Jochems C, Marte JL, Farsaci B, et al. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res. 2014;2(2):133-41. doi: 10.1158/2326-6066.cir-13-0108.
59. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7.
60. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-12. doi: 10.1056/NEJMoa040720.
61. Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N, et al. Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer. J Clin Oncol. 2016;34(22):2636-43. doi: 10.1200/jco.2016.66.9697.